$GLS News
Last published 3y ago
- 3y agoGLSPEARSGHTSight Sciences Appoints Ali Bauerlein as Chief Financial OfficerGlobeNewswireMENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to
- 3y agoGLSGelesis Reports Fourth Quarter and Full Year 2022 ResultsBusiness WireGelesis has demonstrated strong demand for Plenity, helping over 200,000 people on their weight loss journeys since launch Company has filed with FDA to make Plenity available to Over the Counter (OTC), which should
- 3y agoGLSGelesis to Participate in the 25th Annual ICR ConferenceBusiness WireGelesis (NYSE:GLS), the maker of Plenity for weight management, today announced that the Company will participate in the 25th Annual ICR Conference in Orlando, Florida on Monday, January 9, 2023. This press release
- 3y agoAKLIBIIBGLSKRTX+2PureTech Provides End of Year Report on Key ProgressBusiness WireRapid advancement of PureTech's Wholly Owned Pipeline, with three clinical trials now underway and five completed this year that demonstrated compelling safety and tolerability data for LYT-100 (deupirfenidone) and
- 3y agoGLSGelesis Reports Upcoming Participation in Wolfe Research's Annual Consumer Growth ConferenceBusiness WireGelesis Holdings, Inc. (NYSE:GLS) ("Gelesis" or the "Company"), the maker of Plenity for weight management, today announced that its Chief Operating & Commercial Officer, David Pass, Pharm.D., will be featured in a
- 3y agoGLSGelesis Receives Notice of NYSE Market Capitalization Listing Rule Non-ComplianceBusiness WireThe Company Intends to Cure Deficiency and Return to Compliance with NYSE Listing Standard Gelesis Holdings Inc. (NYSE:GLS) ("Gelesis" or the "Company") today noted that on November 16, 2022, the Company received a
- 3y agoGLSGelesis Reports Third Quarter 2022 ResultsBusiness WirePlenity quarterly product revenue increased 114% year-over-year to $6.4 million, with 23,500 new members and 92,000 units sold in Q3 Quarterly gross profit increased by $2.6 million year-over-year, with gross margin
- 4y agoGLSGelesis to Report Third Quarter 2022 Financial Results on November 14, 2022Business WireGelesis Holdings, Inc. (NYSE:GLS) ("Gelesis" or the "Company"), the maker of Plenity® for weight management, today announced that the Company will report financial results for the third quarter ended September 30,
- 4y agoGLSGelesis Receives Notice of NYSE Trading Share Price Listing Rule Non-ComplianceBusiness WireThe Company Intends to Cure Deficiency and Return to Compliance with NYSE Listing Standard Gelesis Holdings Inc. (NYSE:GLS) ("Gelesis" or the "Company") today noted that the Company received a notification letter from
- 4y agoGLSData Presented at Obesity Week Demonstrate that Gelesis Investigational Clinical-Stage Oral Superabsorbent Hydrogel Gel-B Preferentially Enhances the Growth of Akkermansia muciniphila in Preclinical Models Compared to PrebioticsBusiness WireAkkermansia muciniphila has been associated with thickened mucosal lining of the gut, improved gut barrier function, and lean body mass Gelesis Holdings Inc. (NYSE:GLS) ("Gelesis" or the "Company") the maker of Plenity
- 4y agoGLSDr. Frank Greenway to Present Data from the LIGHT-UP Study with Gelesis' Oral Hydrogel Treatment GS200 at Obesity WeekBusiness WireWaist to Height Ratio, known to be correlated with insulin resistance & metabolic syndrome, was a predictor of weight loss response in the study based on a post-hoc analysis As previously reported, the LIGHT-UP
- 4y agoGLSGelesis to Participate in the Jefferies Virtual Fitness & Wellness SummitBusiness WireGelesis Holdings Inc. (NYSE:GLS) ("Gelesis" or the "Company"), the maker of Plenity for weight management, today announced that Yishai Zohar, Founder and Chief Executive Officer, Elliot Maltz, Chief Financial Officer, and David Pass, Chief Operating and
- 4y agoGLSClinical Data from the LIGHT-UP Study Presented at the International Congress of Endocrinology Suggests New Gelesis Oral Hydrogel May Improve Insulin Sensitivity and Favorably Impact Metabolic SyndromeBusiness WireThe 25-week weight loss study which achieved its previously reported primary endpoints also examined the effects of GS200 on insulin resistance Gelesis Holdings Inc. (NYSE:GLS) ("Gelesis" or the "Company") the maker of Plenity for weight management,
- 4y agoAKLICPSRDNAAGLS+4PureTech Health plc – Half-Year ReportBusiness WireStrong capital base with PureTech Level Cash and Cash Equivalents of $341.4 million1 and Consolidated Cash and Cash Equivalents of $365.9 million2 as of June 30, 2022, excluding up to $115.4 million added post-period3; Operational runway extended into Q
- 4y agoGLSGelesis to Participate in Fireside Chat with IPO Edge Today at 2:00 PM ETBusiness WireGelesis Holdings Inc. (NYSE:GLS) ("Gelesis" or the "Company") the maker of Plenity for weight management, today announced that the Company is participating in a fireside chat with IPO Edge today at 2:00 PM ET. The fireside chat will be hosted by Yish
- 4y agoGLSGelesis Reports Second Quarter 2022 ResultsBusiness WirePlenity Q2 product revenue increased 312% year-over-year to $9.0 million Gross profit in Q2 increased by $4.0 million year-over-year, with gross margin improving to 47% from 8% Gelesis (NYSE:GLS), the maker of Plenity for weight management, today
- 4y agoGLSGelesis to Report Second Quarter 2022 Financial Results on August 15, 2022Business WireGelesis Holdings, Inc. (NYSE:GLS) ("Gelesis" or the "Company"), the maker of Plenity® for weight management, today announced that the Company will report financial results for the Second Quarter ended June 30, 2022, on August 15, 2022 prior to the mark
- 4y agoGLSGelesis Announces Additional $15 Million Pre-Order for Plenity®, Bringing Total Pre-Paid Orders from Ro for Plenity to $55 MillionBusiness WireFollowing the successful debut of the national broad awareness media campaign, with a new record-high for prescription requests, the company's telehealth distribution partner, Ro, placed an additional pre-order for the weight management product Geles
- 4y agoGLSOver the Past Decade, Person-First Language Was Used in Only About Half of Diabetes-Focused Articles and Fewer than 1% of Obesity Articles, Finds New StudyBusiness WireNew research from Gelesis highlights ongoing stigmatization of people with obesity and diabetes Gelesis (NYSE:GLS), the maker of Plenity for weight management, presented new findings about the role of language in obesity and diabetes scientific liter
- 4y agoGLSMicrobiota Transplantation Demonstrates How Gut Bacteria Contributes to Weight Loss and Beneficial Metabolic Effects with Gelesis' Proprietary HydrogelBusiness WireNew preclinical data presented today at the American Diabetes Association's annual conference suggests that the company's superabsorbent hydrogel causes changes to the microbiota leading to weight loss and improvements in glucose tolerance and insulin s
- 4y agoGLSGelesis to Participate in Upcoming Investor ConferencesBusiness WireGelesis (NYSE:GLS), the maker of Plenity for weight management, today announced that Yishai Zohar, Founder and Chief Executive Officer, Elliot Maltz, Chief Financial Officer, and David Pass, Chief Operating and Commercial Officer, will participate in tw
- 4y agoGLSGelesis Reports First Quarter 2022 ResultsBusiness WirePlenity product revenue increased 142% year-over-year to $7.5 million in the quarter, driven by the debut of the national media campaign in February 2022 Q1 2022 gross margin increased 277% year-over-year Company reiterates guidance of $58M in pro
- 4y agoGLSGelesis Holdings Inc. (GLS) Q1 2022 Earnings Call TranscriptEarnings Call TranscriptsGLS earnings call for the period ending March 31, 2022.
- 4y agoGLSGelesis to Report First Quarter 2022 Financial Results on May 12, 2022Business WireGelesis (NYSE:GLS), the maker of Plenity® for weight management, today announced that the Company will report financial results for the First Quarter ended March 31, 2022, on May 12, 2022 following the market close. Gelesis management will host a live
- 4y agoCPSRGLSPRTCPureTech Founded Entity Gelesis Announces Clinical Data Demonstrating Weight Loss with GS200 in Adults with Prediabetes and Type 2 Diabetes Presented at the European Congress on Obesity 2022Business WireGelesis' six-month study of weight loss in adults with overweight or obesity who have prediabetes or type 2 diabetes met both of its primary endpoints: the proportion of participants who achieved at least 5% body weight loss (i.e., "Categorical") and th
- 4y agoGLSClinical Data Presented at the European Congress on Obesity 2022 Demonstrates Weight Loss With GS200 in Adults With Prediabetes and Type 2 DiabetesBusiness WireGelesis' six-month study of weight loss in adults with overweight or obesity who have prediabetes or type 2 diabetes met both of its primary endpoints: the proportion of participants who achieved at least 5% body weight loss (i.e., "Categorical") and th
- 4y agoCPSRGLSPRTCPureTech Founded Entity Gelesis Announces its Proprietary Superabsorbent Hydrogel Induced Beneficial Changes to the Gut Microbiota and Expanded Akkermansia, a Bacterial Species Associated with Gut Health and Weight Loss, in New StudyBusiness WireNew preclinical data presented today at the World of Microbiome Conference suggest adding superabsorbent hydrogel to a high-fat "western-like" diet prevents unfavorable changes in the communities of gut bacteria associated with diet-induced weight gain
- 4y agoGLSGelesis' Proprietary Superabsorbent Hydrogel Induced Beneficial Changes to the Gut Microbiota and Expanded Akkermansia, a Bacterial Species Associated with Gut Health and Weight Loss, in New StudyBusiness WireNew pre-clinical data presented today at the World of Microbiome Conference suggest adding superabsorbent hydrogel to a high-fat "western-like" diet prevents unfavorable changes in the communities of gut bacteria associated with diet-induced weight gain
- 4y agoGLSGelesis® Reports Fiscal Year 2021 Results and Fiscal Year 2022 Financial OutlookBusiness WireThe Company ended the year with 79,100 total members for Plenity®, demonstrating strong demand ahead of first quarter 2022 debut media campaign Gelesis reaffirms guidance for $58 million in product revenue and anticipates 400% growth in 2022 followi
- 4y agoGLSGelesis to Report Full Year 2021 Financial Results on March 24, 2022Business WireGelesis (NYSE:GLS), the maker of Plenity® for weight management, today announced that the Company will report financial results for fiscal year 2021 on March 24, 2022, following the market close. Gelesis management will host a live conference call and
- 4y agoGLSPRTCPureTech Founded Entity Gelesis® Releases Preliminary National Launch Results for Plenity®: Record-Breaking Levels of Prescriptions and Online TrafficBusiness WireNew Plenity patient prescriptions increased 3.5-fold within the first three weeks of the national media campaign launch Gelesis has projected $58 million in net revenue in this first full launch year 2022 PureTech Health plc (NASDAQ:PRTC, LSE: PRT
- 4y agoGLSGelesis® Releases Preliminary National Launch Results for Plenity®: Record-Breaking Levels of Prescriptions and Online TrafficBusiness WireNew Plenity patient prescriptions increased 3.5-fold within the first three weeks of the national media campaign launch The company has projected $58 million in net revenue in this first full launch year 2022 Gelesis (NYSE:GLS), the maker of Pl
- 4y agoGLSPRTCPureTech Founded Entity Gelesis to Launch Plenity® National Media Campaign That Challenges Restrictive Dieting NormsBusiness WirePlenity is designed to help people feel satisfied with smaller portions so they can eat less and lose weight, while enjoying the foods they love Gelesis®, the maker of Plenity, began trading on the New York Stock Exchange earlier this month PureT
- 4y agoGLSPlenity® National Media Campaign Kicking Off Today Challenges Restrictive Dieting NormsBusiness WirePlenity is designed to help people feel satisfied with smaller portions so they can eat less and lose weight, while enjoying the foods they love Gelesis®, the maker of Plenity, began trading on the New York Stock Exchange earlier this month Who s
- 4y agoDNAAGLSKRTXPRTC+1PureTech Founded Entity Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. IBusiness WireIn addition to PureTech's advanced Wholly Owned Pipeline, Founded Entities are an additional source of value and Akili is now set to join the growing list of publicly-traded Founded Entities for PureTech, which also include Karuna Therapeutics (NASDAQ:K